This pipeline computes the correlation between significant arm-level copy number variations (cnvs) and selected clinical features.
Testing the association between copy number variation 82 arm-level events and 4 clinical features across 539 patients, 158 significant findings detected with Q value < 0.25.
-
1p gain cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
2p gain cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
2q gain cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
3p gain cnv correlated to 'HISTOLOGICAL_TYPE'.
-
3q gain cnv correlated to 'Time to Death', 'RADIATION_THERAPY', and 'HISTOLOGICAL_TYPE'.
-
4p gain cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
4q gain cnv correlated to 'HISTOLOGICAL_TYPE' and 'RESIDUAL_TUMOR'.
-
5p gain cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
5q gain cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
6p gain cnv correlated to 'RADIATION_THERAPY', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
6q gain cnv correlated to 'HISTOLOGICAL_TYPE' and 'RESIDUAL_TUMOR'.
-
7p gain cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
7q gain cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
8p gain cnv correlated to 'Time to Death' and 'RADIATION_THERAPY'.
-
8q gain cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
9p gain cnv correlated to 'RADIATION_THERAPY' and 'RESIDUAL_TUMOR'.
-
9q gain cnv correlated to 'RESIDUAL_TUMOR'.
-
11p gain cnv correlated to 'HISTOLOGICAL_TYPE'.
-
11q gain cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
12p gain cnv correlated to 'HISTOLOGICAL_TYPE'.
-
12q gain cnv correlated to 'HISTOLOGICAL_TYPE'.
-
13q gain cnv correlated to 'RADIATION_THERAPY' and 'HISTOLOGICAL_TYPE'.
-
14q gain cnv correlated to 'HISTOLOGICAL_TYPE'.
-
15q gain cnv correlated to 'Time to Death' and 'RESIDUAL_TUMOR'.
-
16p gain cnv correlated to 'HISTOLOGICAL_TYPE'.
-
16q gain cnv correlated to 'RESIDUAL_TUMOR'.
-
17p gain cnv correlated to 'HISTOLOGICAL_TYPE'.
-
17q gain cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
18p gain cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
18q gain cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
19p gain cnv correlated to 'HISTOLOGICAL_TYPE'.
-
19q gain cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
20p gain cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
20q gain cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
21q gain cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
22q gain cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
xq gain cnv correlated to 'Time to Death'.
-
1p loss cnv correlated to 'HISTOLOGICAL_TYPE' and 'RESIDUAL_TUMOR'.
-
1q loss cnv correlated to 'HISTOLOGICAL_TYPE' and 'RESIDUAL_TUMOR'.
-
2p loss cnv correlated to 'Time to Death'.
-
2q loss cnv correlated to 'Time to Death'.
-
3p loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
3q loss cnv correlated to 'HISTOLOGICAL_TYPE'.
-
4p loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
4q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
5p loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
5q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
6p loss cnv correlated to 'HISTOLOGICAL_TYPE'.
-
6q loss cnv correlated to 'HISTOLOGICAL_TYPE'.
-
7p loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
7q loss cnv correlated to 'HISTOLOGICAL_TYPE'.
-
8p loss cnv correlated to 'Time to Death', 'RADIATION_THERAPY', and 'HISTOLOGICAL_TYPE'.
-
8q loss cnv correlated to 'HISTOLOGICAL_TYPE'.
-
9p loss cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
9q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
10p loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
10q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
11p loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
11q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
12p loss cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
12q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
13q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
14q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
15q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
16p loss cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
16q loss cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
17p loss cnv correlated to 'Time to Death', 'RADIATION_THERAPY', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
17q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
18p loss cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
18q loss cnv correlated to 'HISTOLOGICAL_TYPE' and 'RESIDUAL_TUMOR'.
-
19p loss cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
19q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
20p loss cnv correlated to 'HISTOLOGICAL_TYPE'.
-
20q loss cnv correlated to 'HISTOLOGICAL_TYPE'.
-
21q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
22q loss cnv correlated to 'Time to Death' and 'HISTOLOGICAL_TYPE'.
-
xp loss cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
-
xq loss cnv correlated to 'Time to Death', 'HISTOLOGICAL_TYPE', and 'RESIDUAL_TUMOR'.
Clinical Features |
Time to Death |
RADIATION THERAPY |
HISTOLOGICAL TYPE |
RESIDUAL TUMOR |
||
nCNV (%) | nWild-Type | logrank test | Fisher's exact test | Fisher's exact test | Fisher's exact test | |
17p loss | 129 (24%) | 410 |
4.07e-05 (0.000212) |
0.0731 (0.165) |
1e-05 (6.31e-05) |
0.0847 (0.189) |
1p gain | 54 (10%) | 485 |
0.0593 (0.142) |
0.231 (0.387) |
4e-05 (0.000212) |
0.092 (0.201) |
3q gain | 85 (16%) | 454 |
0.000773 (0.00317) |
0.00699 (0.0236) |
1e-05 (6.31e-05) |
0.205 (0.364) |
4p gain | 14 (3%) | 525 |
0.0247 (0.0674) |
0.414 (0.572) |
0.00145 (0.00553) |
0.1 (0.215) |
5p gain | 52 (10%) | 487 |
3.18e-07 (6.31e-05) |
0.647 (0.775) |
1e-05 (6.31e-05) |
0.0938 (0.204) |
6p gain | 81 (15%) | 458 |
0.164 (0.309) |
0.0598 (0.142) |
1e-05 (6.31e-05) |
0.0565 (0.139) |
17q gain | 30 (6%) | 509 |
0.0125 (0.0392) |
0.441 (0.603) |
2e-05 (0.000111) |
0.0243 (0.067) |
18p gain | 73 (14%) | 466 |
0.0302 (0.08) |
0.798 (0.861) |
1e-05 (6.31e-05) |
0.019 (0.0548) |
18q gain | 46 (9%) | 493 |
0.00715 (0.0239) |
0.753 (0.839) |
1e-05 (6.31e-05) |
0.0113 (0.0364) |
20p gain | 109 (20%) | 430 |
0.000131 (0.000653) |
0.738 (0.837) |
1e-05 (6.31e-05) |
0.0171 (0.0498) |
20q gain | 130 (24%) | 409 |
1.54e-05 (9.37e-05) |
1 (1.00) |
1e-05 (6.31e-05) |
0.0041 (0.0143) |
22q gain | 30 (6%) | 509 |
0.117 (0.245) |
1 (1.00) |
1e-05 (6.31e-05) |
0.024 (0.0667) |
8p loss | 78 (14%) | 461 |
0.0167 (0.0488) |
0.015 (0.0453) |
1e-05 (6.31e-05) |
0.304 (0.456) |
9p loss | 99 (18%) | 440 |
3.24e-05 (0.000174) |
0.908 (0.937) |
1e-05 (6.31e-05) |
0.0763 (0.171) |
12p loss | 45 (8%) | 494 |
0.000375 (0.00171) |
0.753 (0.839) |
1e-05 (6.31e-05) |
0.0526 (0.132) |
16p loss | 99 (18%) | 440 |
9.49e-06 (6.31e-05) |
0.728 (0.837) |
1e-05 (6.31e-05) |
0.0575 (0.14) |
16q loss | 140 (26%) | 399 |
0.00374 (0.0133) |
0.539 (0.68) |
1e-05 (6.31e-05) |
0.0599 (0.142) |
18p loss | 51 (9%) | 488 |
0.0679 (0.156) |
0.64 (0.774) |
0.00034 (0.00157) |
0.0663 (0.154) |
19p loss | 57 (11%) | 482 |
0.00582 (0.0199) |
0.765 (0.839) |
1e-05 (6.31e-05) |
0.0873 (0.192) |
xp loss | 86 (16%) | 453 |
2.06e-05 (0.000112) |
0.808 (0.868) |
1e-05 (6.31e-05) |
0.0572 (0.14) |
xq loss | 70 (13%) | 469 |
0.000752 (0.00312) |
0.181 (0.332) |
1e-05 (6.31e-05) |
0.097 (0.209) |
2p gain | 93 (17%) | 446 |
4.85e-07 (6.31e-05) |
0.237 (0.395) |
1e-05 (6.31e-05) |
0.763 (0.839) |
2q gain | 78 (14%) | 461 |
6.83e-07 (6.31e-05) |
0.127 (0.259) |
1e-05 (6.31e-05) |
0.377 (0.535) |
4q gain | 8 (1%) | 531 |
0.434 (0.596) |
0.704 (0.814) |
0.0272 (0.0731) |
0.119 (0.247) |
5q gain | 20 (4%) | 519 |
0.0128 (0.0395) |
0.641 (0.774) |
0.00044 (0.00195) |
0.251 (0.41) |
6q gain | 66 (12%) | 473 |
0.166 (0.309) |
0.409 (0.569) |
2e-05 (0.000111) |
0.0226 (0.064) |
7p gain | 68 (13%) | 471 |
0.0114 (0.0365) |
0.893 (0.933) |
0.0237 (0.0664) |
0.389 (0.544) |
7q gain | 65 (12%) | 474 |
0.00064 (0.0028) |
0.779 (0.849) |
0.103 (0.219) |
0.502 (0.653) |
8p gain | 116 (22%) | 423 |
0.0872 (0.192) |
0.05 (0.126) |
0.758 (0.839) |
0.153 (0.299) |
8q gain | 159 (29%) | 380 |
0.0119 (0.0376) |
0.493 (0.648) |
0.00395 (0.0139) |
0.187 (0.338) |
9p gain | 22 (4%) | 517 |
0.301 (0.455) |
0.108 (0.228) |
0.144 (0.284) |
0.0494 (0.126) |
11q gain | 20 (4%) | 519 |
0.0054 (0.0187) |
0.255 (0.412) |
0.0131 (0.0403) |
0.215 (0.372) |
13q gain | 30 (6%) | 509 |
0.474 (0.634) |
0.0354 (0.0921) |
1e-05 (6.31e-05) |
0.309 (0.461) |
15q gain | 11 (2%) | 528 |
0.0137 (0.0415) |
0.124 (0.254) |
0.818 (0.877) |
0.0459 (0.118) |
19q gain | 58 (11%) | 481 |
0.000841 (0.00336) |
0.667 (0.788) |
1e-05 (6.31e-05) |
0.482 (0.639) |
21q gain | 39 (7%) | 500 |
0.0669 (0.155) |
0.228 (0.386) |
1e-05 (6.31e-05) |
0.25 (0.41) |
1p loss | 27 (5%) | 512 |
0.287 (0.44) |
0.164 (0.309) |
1e-05 (6.31e-05) |
0.00266 (0.00969) |
1q loss | 16 (3%) | 523 |
0.21 (0.37) |
0.444 (0.604) |
0.00066 (0.00285) |
0.016 (0.0476) |
3p loss | 52 (10%) | 487 |
0.0108 (0.035) |
0.88 (0.924) |
1e-05 (6.31e-05) |
0.785 (0.852) |
4p loss | 106 (20%) | 433 |
0.00202 (0.00744) |
0.735 (0.837) |
1e-05 (6.31e-05) |
0.347 (0.502) |
4q loss | 104 (19%) | 435 |
0.00013 (0.000653) |
0.91 (0.937) |
1e-05 (6.31e-05) |
0.641 (0.774) |
5p loss | 53 (10%) | 486 |
0.0214 (0.0609) |
0.458 (0.617) |
1e-05 (6.31e-05) |
0.172 (0.319) |
5q loss | 73 (14%) | 466 |
0.000238 (0.00115) |
0.52 (0.669) |
1e-05 (6.31e-05) |
0.763 (0.839) |
7p loss | 45 (8%) | 494 |
0.036 (0.093) |
1 (1.00) |
1e-05 (6.31e-05) |
0.216 (0.372) |
9q loss | 117 (22%) | 422 |
0.000249 (0.00118) |
0.745 (0.839) |
1e-05 (6.31e-05) |
0.326 (0.478) |
10p loss | 44 (8%) | 495 |
0.0334 (0.0876) |
0.507 (0.658) |
1e-05 (6.31e-05) |
0.276 (0.429) |
10q loss | 40 (7%) | 499 |
0.0651 (0.154) |
0.496 (0.648) |
1e-05 (6.31e-05) |
0.642 (0.774) |
11p loss | 76 (14%) | 463 |
1.48e-05 (9.16e-05) |
0.796 (0.861) |
1e-05 (6.31e-05) |
0.287 (0.44) |
11q loss | 73 (14%) | 466 |
0.000163 (0.000798) |
0.51 (0.658) |
1e-05 (6.31e-05) |
0.191 (0.345) |
12q loss | 40 (7%) | 499 |
0.000276 (0.00129) |
0.74 (0.837) |
1e-05 (6.31e-05) |
0.688 (0.797) |
13q loss | 93 (17%) | 446 |
0.00068 (0.00286) |
0.341 (0.495) |
1e-05 (6.31e-05) |
0.764 (0.839) |
14q loss | 62 (12%) | 477 |
0.00162 (0.00612) |
0.67 (0.788) |
1e-05 (6.31e-05) |
0.637 (0.774) |
15q loss | 109 (20%) | 430 |
0.00272 (0.00981) |
0.912 (0.937) |
1e-05 (6.31e-05) |
0.495 (0.648) |
17q loss | 93 (17%) | 446 |
0.0018 (0.00671) |
0.192 (0.345) |
1e-05 (6.31e-05) |
0.246 (0.407) |
18q loss | 63 (12%) | 476 |
0.141 (0.283) |
0.314 (0.464) |
1e-05 (6.31e-05) |
0.0723 (0.165) |
19q loss | 54 (10%) | 485 |
0.0535 (0.133) |
0.647 (0.775) |
1e-05 (6.31e-05) |
0.248 (0.408) |
21q loss | 54 (10%) | 485 |
0.000828 (0.00335) |
1 (1.00) |
1e-05 (6.31e-05) |
0.262 (0.412) |
22q loss | 110 (20%) | 429 |
0.000676 (0.00286) |
0.91 (0.937) |
1e-05 (6.31e-05) |
0.203 (0.363) |
3p gain | 48 (9%) | 491 |
0.373 (0.534) |
0.753 (0.839) |
0.0004 (0.0018) |
0.382 (0.539) |
9q gain | 10 (2%) | 529 |
0.28 (0.434) |
0.476 (0.634) |
0.26 (0.412) |
0.00752 (0.0249) |
11p gain | 23 (4%) | 516 |
0.257 (0.412) |
0.83 (0.884) |
2e-05 (0.000111) |
0.181 (0.332) |
12p gain | 69 (13%) | 470 |
0.935 (0.958) |
1 (1.00) |
1e-05 (6.31e-05) |
0.671 (0.788) |
12q gain | 51 (9%) | 488 |
0.434 (0.596) |
0.654 (0.78) |
0.0657 (0.154) |
0.532 (0.674) |
14q gain | 36 (7%) | 503 |
0.256 (0.412) |
0.604 (0.754) |
2e-05 (0.000111) |
0.374 (0.534) |
16p gain | 25 (5%) | 514 |
0.882 (0.924) |
0.674 (0.788) |
0.0163 (0.0482) |
0.146 (0.288) |
16q gain | 10 (2%) | 529 |
0.294 (0.448) |
0.525 (0.67) |
0.262 (0.412) |
0.00946 (0.031) |
17p gain | 13 (2%) | 526 |
0.295 (0.448) |
0.771 (0.843) |
0.104 (0.22) |
0.166 (0.309) |
19p gain | 55 (10%) | 484 |
0.265 (0.413) |
0.556 (0.698) |
1e-05 (6.31e-05) |
0.642 (0.774) |
xq gain | 64 (12%) | 475 |
0.0258 (0.07) |
0.213 (0.372) |
0.305 (0.456) |
0.155 (0.302) |
2p loss | 12 (2%) | 527 |
0.0281 (0.075) |
0.124 (0.254) |
0.214 (0.372) |
0.186 (0.338) |
2q loss | 18 (3%) | 521 |
0.00123 (0.00482) |
0.134 (0.271) |
0.143 (0.284) |
0.531 (0.674) |
3q loss | 31 (6%) | 508 |
0.559 (0.699) |
0.341 (0.495) |
0.00012 (0.000615) |
0.351 (0.506) |
6p loss | 20 (4%) | 519 |
0.737 (0.837) |
0.227 (0.386) |
2e-05 (0.000111) |
0.383 (0.539) |
6q loss | 25 (5%) | 514 |
0.522 (0.669) |
0.674 (0.788) |
1e-05 (6.31e-05) |
0.314 (0.464) |
7q loss | 45 (8%) | 494 |
0.16 (0.307) |
0.634 (0.774) |
1e-05 (6.31e-05) |
0.637 (0.774) |
8q loss | 22 (4%) | 517 |
0.9 (0.937) |
0.483 (0.639) |
1e-05 (6.31e-05) |
0.317 (0.466) |
20p loss | 22 (4%) | 517 |
0.624 (0.774) |
0.261 (0.412) |
0.001 (0.00395) |
0.162 (0.309) |
20q loss | 11 (2%) | 528 |
0.822 (0.878) |
0.223 (0.381) |
0.00135 (0.00521) |
0.856 (0.903) |
1q gain | 189 (35%) | 350 |
0.144 (0.284) |
1 (1.00) |
0.39 (0.544) |
0.947 (0.965) |
10p gain | 116 (22%) | 423 |
0.946 (0.965) |
0.459 (0.617) |
0.739 (0.837) |
0.848 (0.897) |
10q gain | 108 (20%) | 431 |
0.675 (0.788) |
0.23 (0.386) |
0.833 (0.884) |
0.217 (0.372) |
xp gain | 63 (12%) | 476 |
0.259 (0.412) |
0.677 (0.788) |
0.455 (0.617) |
0.158 (0.306) |
P value = 0.0593 (logrank test), Q value = 0.14
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
1P GAIN MUTATED | 54 | 13 | 0.1 - 109.1 (24.3) |
1P GAIN WILD-TYPE | 483 | 77 | 0.2 - 225.5 (30.0) |
P value = 4e-05 (Fisher's exact test), Q value = 0.00021
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
1P GAIN MUTATED | 27 | 2 | 25 |
1P GAIN WILD-TYPE | 377 | 20 | 88 |
P value = 0.092 (Fisher's exact test), Q value = 0.2
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
1P GAIN MUTATED | 31 | 1 | 2 | 8 |
1P GAIN WILD-TYPE | 340 | 21 | 14 | 32 |
P value = 4.85e-07 (logrank test), Q value = 6.3e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
2P GAIN MUTATED | 92 | 31 | 0.1 - 149.6 (23.9) |
2P GAIN WILD-TYPE | 445 | 59 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
2P GAIN MUTATED | 43 | 5 | 45 |
2P GAIN WILD-TYPE | 361 | 17 | 68 |
P value = 6.83e-07 (logrank test), Q value = 6.3e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
2Q GAIN MUTATED | 77 | 26 | 0.1 - 110.1 (23.3) |
2Q GAIN WILD-TYPE | 460 | 64 | 0.1 - 225.5 (30.6) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
2Q GAIN MUTATED | 37 | 4 | 37 |
2Q GAIN WILD-TYPE | 367 | 18 | 76 |
P value = 4e-04 (Fisher's exact test), Q value = 0.0018
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
3P GAIN MUTATED | 27 | 0 | 21 |
3P GAIN WILD-TYPE | 377 | 22 | 92 |
P value = 0.000773 (logrank test), Q value = 0.0032
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
3Q GAIN MUTATED | 85 | 25 | 0.1 - 225.5 (27.4) |
3Q GAIN WILD-TYPE | 452 | 65 | 0.2 - 185.8 (30.0) |
P value = 0.00699 (Fisher's exact test), Q value = 0.024
nPatients | NO | YES |
---|---|---|
ALL | 290 | 224 |
3Q GAIN MUTATED | 34 | 46 |
3Q GAIN WILD-TYPE | 256 | 178 |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
3Q GAIN MUTATED | 37 | 4 | 44 |
3Q GAIN WILD-TYPE | 367 | 18 | 69 |
P value = 0.0247 (logrank test), Q value = 0.067
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
4P GAIN MUTATED | 14 | 5 | 5.9 - 97.7 (22.3) |
4P GAIN WILD-TYPE | 523 | 85 | 0.1 - 225.5 (29.9) |
P value = 0.00145 (Fisher's exact test), Q value = 0.0055
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
4P GAIN MUTATED | 5 | 0 | 9 |
4P GAIN WILD-TYPE | 399 | 22 | 104 |
P value = 0.1 (Fisher's exact test), Q value = 0.22
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
4P GAIN MUTATED | 10 | 1 | 2 | 0 |
4P GAIN WILD-TYPE | 361 | 21 | 14 | 40 |
P value = 0.0272 (Fisher's exact test), Q value = 0.073
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
4Q GAIN MUTATED | 3 | 0 | 5 |
4Q GAIN WILD-TYPE | 401 | 22 | 108 |
P value = 0.119 (Fisher's exact test), Q value = 0.25
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
4Q GAIN MUTATED | 4 | 1 | 1 | 0 |
4Q GAIN WILD-TYPE | 367 | 21 | 15 | 40 |
P value = 3.18e-07 (logrank test), Q value = 6.3e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
5P GAIN MUTATED | 52 | 20 | 0.4 - 110.1 (22.9) |
5P GAIN WILD-TYPE | 485 | 70 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
5P GAIN MUTATED | 16 | 3 | 33 |
5P GAIN WILD-TYPE | 388 | 19 | 80 |
P value = 0.0938 (Fisher's exact test), Q value = 0.2
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
5P GAIN MUTATED | 37 | 2 | 5 | 4 |
5P GAIN WILD-TYPE | 334 | 20 | 11 | 36 |
P value = 0.0128 (logrank test), Q value = 0.04
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
5Q GAIN MUTATED | 20 | 7 | 1.4 - 79.1 (27.9) |
5Q GAIN WILD-TYPE | 517 | 83 | 0.1 - 225.5 (29.9) |
P value = 0.00044 (Fisher's exact test), Q value = 0.002
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
5Q GAIN MUTATED | 8 | 0 | 12 |
5Q GAIN WILD-TYPE | 396 | 22 | 101 |
P value = 0.0598 (Fisher's exact test), Q value = 0.14
nPatients | NO | YES |
---|---|---|
ALL | 290 | 224 |
6P GAIN MUTATED | 35 | 41 |
6P GAIN WILD-TYPE | 255 | 183 |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
6P GAIN MUTATED | 40 | 1 | 40 |
6P GAIN WILD-TYPE | 364 | 21 | 73 |
P value = 0.0565 (Fisher's exact test), Q value = 0.14
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
6P GAIN MUTATED | 46 | 2 | 3 | 11 |
6P GAIN WILD-TYPE | 325 | 20 | 13 | 29 |
P value = 2e-05 (Fisher's exact test), Q value = 0.00011
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
6Q GAIN MUTATED | 35 | 1 | 30 |
6Q GAIN WILD-TYPE | 369 | 21 | 83 |
P value = 0.0226 (Fisher's exact test), Q value = 0.064
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
6Q GAIN MUTATED | 37 | 1 | 3 | 10 |
6Q GAIN WILD-TYPE | 334 | 21 | 13 | 30 |
P value = 0.0114 (logrank test), Q value = 0.036
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
7P GAIN MUTATED | 67 | 17 | 0.2 - 125.4 (21.9) |
7P GAIN WILD-TYPE | 470 | 73 | 0.1 - 225.5 (30.3) |
P value = 0.0237 (Fisher's exact test), Q value = 0.066
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
7P GAIN MUTATED | 42 | 4 | 22 |
7P GAIN WILD-TYPE | 362 | 18 | 91 |
P value = 0.00064 (logrank test), Q value = 0.0028
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
7Q GAIN MUTATED | 64 | 18 | 0.2 - 125.4 (20.2) |
7Q GAIN WILD-TYPE | 473 | 72 | 0.1 - 225.5 (30.7) |
P value = 0.103 (Fisher's exact test), Q value = 0.22
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
7Q GAIN MUTATED | 42 | 4 | 19 |
7Q GAIN WILD-TYPE | 362 | 18 | 94 |
P value = 0.0872 (logrank test), Q value = 0.19
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
8P GAIN MUTATED | 115 | 25 | 0.1 - 225.5 (31.1) |
8P GAIN WILD-TYPE | 422 | 65 | 0.1 - 185.8 (29.8) |
P value = 0.05 (Fisher's exact test), Q value = 0.13
nPatients | NO | YES |
---|---|---|
ALL | 290 | 224 |
8P GAIN MUTATED | 70 | 38 |
8P GAIN WILD-TYPE | 220 | 186 |
P value = 0.0119 (logrank test), Q value = 0.038
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
8Q GAIN MUTATED | 157 | 37 | 0.1 - 225.5 (30.1) |
8Q GAIN WILD-TYPE | 380 | 53 | 0.2 - 185.8 (29.8) |
P value = 0.00395 (Fisher's exact test), Q value = 0.014
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
8Q GAIN MUTATED | 104 | 8 | 47 |
8Q GAIN WILD-TYPE | 300 | 14 | 66 |
P value = 0.108 (Fisher's exact test), Q value = 0.23
nPatients | NO | YES |
---|---|---|
ALL | 290 | 224 |
9P GAIN MUTATED | 15 | 5 |
9P GAIN WILD-TYPE | 275 | 219 |
P value = 0.0494 (Fisher's exact test), Q value = 0.13
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
9P GAIN MUTATED | 12 | 2 | 2 | 3 |
9P GAIN WILD-TYPE | 359 | 20 | 14 | 37 |
P value = 0.00752 (Fisher's exact test), Q value = 0.025
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
9Q GAIN MUTATED | 3 | 1 | 1 | 3 |
9Q GAIN WILD-TYPE | 368 | 21 | 15 | 37 |
P value = 2e-05 (Fisher's exact test), Q value = 0.00011
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
11P GAIN MUTATED | 8 | 0 | 15 |
11P GAIN WILD-TYPE | 396 | 22 | 98 |
P value = 0.0054 (logrank test), Q value = 0.019
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
11Q GAIN MUTATED | 20 | 8 | 2.1 - 92.9 (30.5) |
11Q GAIN WILD-TYPE | 517 | 82 | 0.1 - 225.5 (29.9) |
P value = 0.0131 (Fisher's exact test), Q value = 0.04
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
11Q GAIN MUTATED | 10 | 0 | 10 |
11Q GAIN WILD-TYPE | 394 | 22 | 103 |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
12P GAIN MUTATED | 35 | 3 | 31 |
12P GAIN WILD-TYPE | 369 | 19 | 82 |
P value = 0.0657 (Fisher's exact test), Q value = 0.15
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
12Q GAIN MUTATED | 32 | 2 | 17 |
12Q GAIN WILD-TYPE | 372 | 20 | 96 |
P value = 0.0354 (Fisher's exact test), Q value = 0.092
nPatients | NO | YES |
---|---|---|
ALL | 290 | 224 |
13Q GAIN MUTATED | 11 | 19 |
13Q GAIN WILD-TYPE | 279 | 205 |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
13Q GAIN MUTATED | 8 | 1 | 21 |
13Q GAIN WILD-TYPE | 396 | 21 | 92 |
P value = 2e-05 (Fisher's exact test), Q value = 0.00011
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
14Q GAIN MUTATED | 15 | 2 | 19 |
14Q GAIN WILD-TYPE | 389 | 20 | 94 |
P value = 0.0137 (logrank test), Q value = 0.042
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
15Q GAIN MUTATED | 11 | 4 | 4.4 - 75.7 (20.8) |
15Q GAIN WILD-TYPE | 526 | 86 | 0.1 - 225.5 (30.0) |
P value = 0.0459 (Fisher's exact test), Q value = 0.12
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
15Q GAIN MUTATED | 4 | 1 | 1 | 2 |
15Q GAIN WILD-TYPE | 367 | 21 | 15 | 38 |
P value = 0.0163 (Fisher's exact test), Q value = 0.048
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
16P GAIN MUTATED | 13 | 1 | 11 |
16P GAIN WILD-TYPE | 391 | 21 | 102 |
P value = 0.00946 (Fisher's exact test), Q value = 0.031
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
16Q GAIN MUTATED | 4 | 3 | 0 | 1 |
16Q GAIN WILD-TYPE | 367 | 19 | 16 | 39 |
P value = 0.104 (Fisher's exact test), Q value = 0.22
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
17P GAIN MUTATED | 7 | 0 | 6 |
17P GAIN WILD-TYPE | 397 | 22 | 107 |
P value = 0.0125 (logrank test), Q value = 0.039
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
17Q GAIN MUTATED | 30 | 8 | 0.1 - 78.4 (20.4) |
17Q GAIN WILD-TYPE | 507 | 82 | 0.1 - 225.5 (30.4) |
P value = 2e-05 (Fisher's exact test), Q value = 0.00011
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
17Q GAIN MUTATED | 12 | 0 | 18 |
17Q GAIN WILD-TYPE | 392 | 22 | 95 |
P value = 0.0243 (Fisher's exact test), Q value = 0.067
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
17Q GAIN MUTATED | 18 | 1 | 4 | 3 |
17Q GAIN WILD-TYPE | 353 | 21 | 12 | 37 |
P value = 0.0302 (logrank test), Q value = 0.08
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
18P GAIN MUTATED | 73 | 20 | 0.4 - 125.4 (33.3) |
18P GAIN WILD-TYPE | 464 | 70 | 0.1 - 225.5 (29.4) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
18P GAIN MUTATED | 22 | 5 | 46 |
18P GAIN WILD-TYPE | 382 | 17 | 67 |
P value = 0.019 (Fisher's exact test), Q value = 0.055
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
18P GAIN MUTATED | 47 | 1 | 6 | 8 |
18P GAIN WILD-TYPE | 324 | 21 | 10 | 32 |
P value = 0.00715 (logrank test), Q value = 0.024
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
18Q GAIN MUTATED | 46 | 15 | 3.0 - 125.4 (28.5) |
18Q GAIN WILD-TYPE | 491 | 75 | 0.1 - 225.5 (29.9) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
18Q GAIN MUTATED | 17 | 4 | 25 |
18Q GAIN WILD-TYPE | 387 | 18 | 88 |
P value = 0.0113 (Fisher's exact test), Q value = 0.036
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
18Q GAIN MUTATED | 28 | 0 | 3 | 8 |
18Q GAIN WILD-TYPE | 343 | 22 | 13 | 32 |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
19P GAIN MUTATED | 21 | 3 | 31 |
19P GAIN WILD-TYPE | 383 | 19 | 82 |
P value = 0.000841 (logrank test), Q value = 0.0034
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
19Q GAIN MUTATED | 57 | 18 | 0.1 - 110.1 (25.5) |
19Q GAIN WILD-TYPE | 480 | 72 | 0.2 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
19Q GAIN MUTATED | 16 | 3 | 39 |
19Q GAIN WILD-TYPE | 388 | 19 | 74 |
P value = 0.000131 (logrank test), Q value = 0.00065
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
20P GAIN MUTATED | 109 | 30 | 0.1 - 136.6 (27.0) |
20P GAIN WILD-TYPE | 428 | 60 | 0.1 - 225.5 (30.7) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
20P GAIN MUTATED | 47 | 3 | 59 |
20P GAIN WILD-TYPE | 357 | 19 | 54 |
P value = 0.0171 (Fisher's exact test), Q value = 0.05
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
20P GAIN MUTATED | 63 | 4 | 7 | 12 |
20P GAIN WILD-TYPE | 308 | 18 | 9 | 28 |
P value = 1.54e-05 (logrank test), Q value = 9.4e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
20Q GAIN MUTATED | 129 | 37 | 0.1 - 225.5 (27.1) |
20Q GAIN WILD-TYPE | 408 | 53 | 0.1 - 185.8 (30.7) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
20Q GAIN MUTATED | 58 | 3 | 69 |
20Q GAIN WILD-TYPE | 346 | 19 | 44 |
P value = 0.0041 (Fisher's exact test), Q value = 0.014
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
20Q GAIN MUTATED | 74 | 5 | 9 | 13 |
20Q GAIN WILD-TYPE | 297 | 17 | 7 | 27 |
P value = 0.0669 (logrank test), Q value = 0.15
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
21Q GAIN MUTATED | 39 | 10 | 0.1 - 110.1 (25.5) |
21Q GAIN WILD-TYPE | 498 | 80 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
21Q GAIN MUTATED | 13 | 1 | 25 |
21Q GAIN WILD-TYPE | 391 | 21 | 88 |
P value = 0.117 (logrank test), Q value = 0.25
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
22Q GAIN MUTATED | 29 | 8 | 0.4 - 225.5 (27.9) |
22Q GAIN WILD-TYPE | 508 | 82 | 0.1 - 185.8 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
22Q GAIN MUTATED | 7 | 1 | 22 |
22Q GAIN WILD-TYPE | 397 | 21 | 91 |
P value = 0.024 (Fisher's exact test), Q value = 0.067
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
22Q GAIN MUTATED | 18 | 1 | 4 | 3 |
22Q GAIN WILD-TYPE | 353 | 21 | 12 | 37 |
P value = 0.0258 (logrank test), Q value = 0.07
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
XQ GAIN MUTATED | 64 | 16 | 0.1 - 83.6 (26.4) |
XQ GAIN WILD-TYPE | 473 | 74 | 0.2 - 225.5 (30.0) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
1P LOSS MUTATED | 7 | 3 | 17 |
1P LOSS WILD-TYPE | 397 | 19 | 96 |
P value = 0.00266 (Fisher's exact test), Q value = 0.0097
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
1P LOSS MUTATED | 17 | 3 | 4 | 0 |
1P LOSS WILD-TYPE | 354 | 19 | 12 | 40 |
P value = 0.00066 (Fisher's exact test), Q value = 0.0028
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
1Q LOSS MUTATED | 5 | 2 | 9 |
1Q LOSS WILD-TYPE | 399 | 20 | 104 |
P value = 0.016 (Fisher's exact test), Q value = 0.048
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
1Q LOSS MUTATED | 10 | 1 | 3 | 0 |
1Q LOSS WILD-TYPE | 361 | 21 | 13 | 40 |
P value = 0.0281 (logrank test), Q value = 0.075
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
2P LOSS MUTATED | 12 | 4 | 0.6 - 92.9 (18.9) |
2P LOSS WILD-TYPE | 525 | 86 | 0.1 - 225.5 (29.9) |
P value = 0.00123 (logrank test), Q value = 0.0048
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
2Q LOSS MUTATED | 18 | 7 | 0.6 - 92.9 (21.4) |
2Q LOSS WILD-TYPE | 519 | 83 | 0.1 - 225.5 (30.0) |
P value = 0.0108 (logrank test), Q value = 0.035
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
3P LOSS MUTATED | 52 | 14 | 0.1 - 125.4 (24.9) |
3P LOSS WILD-TYPE | 485 | 76 | 0.1 - 225.5 (30.4) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
3P LOSS MUTATED | 20 | 6 | 26 |
3P LOSS WILD-TYPE | 384 | 16 | 87 |
P value = 0.00012 (Fisher's exact test), Q value = 0.00061
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
3Q LOSS MUTATED | 13 | 2 | 16 |
3Q LOSS WILD-TYPE | 391 | 20 | 97 |
P value = 0.00202 (logrank test), Q value = 0.0074
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
4P LOSS MUTATED | 105 | 28 | 0.2 - 149.6 (27.2) |
4P LOSS WILD-TYPE | 432 | 62 | 0.1 - 225.5 (30.7) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
4P LOSS MUTATED | 34 | 8 | 64 |
4P LOSS WILD-TYPE | 370 | 14 | 49 |
P value = 0.00013 (logrank test), Q value = 0.00065
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
4Q LOSS MUTATED | 103 | 30 | 0.2 - 149.6 (27.9) |
4Q LOSS WILD-TYPE | 434 | 60 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
4Q LOSS MUTATED | 33 | 8 | 63 |
4Q LOSS WILD-TYPE | 371 | 14 | 50 |
P value = 0.0214 (logrank test), Q value = 0.061
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
5P LOSS MUTATED | 53 | 15 | 0.2 - 149.6 (27.1) |
5P LOSS WILD-TYPE | 484 | 75 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
5P LOSS MUTATED | 17 | 1 | 35 |
5P LOSS WILD-TYPE | 387 | 21 | 78 |
P value = 0.000238 (logrank test), Q value = 0.0011
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
5Q LOSS MUTATED | 73 | 23 | 0.2 - 149.6 (27.2) |
5Q LOSS WILD-TYPE | 464 | 67 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
5Q LOSS MUTATED | 20 | 4 | 49 |
5Q LOSS WILD-TYPE | 384 | 18 | 64 |
P value = 2e-05 (Fisher's exact test), Q value = 0.00011
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
6P LOSS MUTATED | 5 | 2 | 13 |
6P LOSS WILD-TYPE | 399 | 20 | 100 |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
6Q LOSS MUTATED | 5 | 1 | 19 |
6Q LOSS WILD-TYPE | 399 | 21 | 94 |
P value = 0.036 (logrank test), Q value = 0.093
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
7P LOSS MUTATED | 45 | 13 | 2.1 - 110.1 (30.7) |
7P LOSS WILD-TYPE | 492 | 77 | 0.1 - 225.5 (29.8) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
7P LOSS MUTATED | 15 | 2 | 28 |
7P LOSS WILD-TYPE | 389 | 20 | 85 |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
7Q LOSS MUTATED | 10 | 2 | 33 |
7Q LOSS WILD-TYPE | 394 | 20 | 80 |
P value = 0.0167 (logrank test), Q value = 0.049
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
8P LOSS MUTATED | 78 | 20 | 0.4 - 110.1 (27.6) |
8P LOSS WILD-TYPE | 459 | 70 | 0.1 - 225.5 (30.1) |
P value = 0.015 (Fisher's exact test), Q value = 0.045
nPatients | NO | YES |
---|---|---|
ALL | 290 | 224 |
8P LOSS MUTATED | 31 | 41 |
8P LOSS WILD-TYPE | 259 | 183 |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
8P LOSS MUTATED | 17 | 4 | 57 |
8P LOSS WILD-TYPE | 387 | 18 | 56 |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
8Q LOSS MUTATED | 1 | 1 | 20 |
8Q LOSS WILD-TYPE | 403 | 21 | 93 |
P value = 3.24e-05 (logrank test), Q value = 0.00017
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
9P LOSS MUTATED | 99 | 32 | 0.3 - 149.6 (27.1) |
9P LOSS WILD-TYPE | 438 | 58 | 0.1 - 225.5 (30.3) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
9P LOSS MUTATED | 34 | 7 | 58 |
9P LOSS WILD-TYPE | 370 | 15 | 55 |
P value = 0.0763 (Fisher's exact test), Q value = 0.17
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
9P LOSS MUTATED | 60 | 5 | 6 | 10 |
9P LOSS WILD-TYPE | 311 | 17 | 10 | 30 |
P value = 0.000249 (logrank test), Q value = 0.0012
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
9Q LOSS MUTATED | 117 | 34 | 0.2 - 136.6 (27.9) |
9Q LOSS WILD-TYPE | 420 | 56 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
9Q LOSS MUTATED | 45 | 9 | 63 |
9Q LOSS WILD-TYPE | 359 | 13 | 50 |
P value = 0.0334 (logrank test), Q value = 0.088
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
10P LOSS MUTATED | 44 | 12 | 0.3 - 125.4 (23.9) |
10P LOSS WILD-TYPE | 493 | 78 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
10P LOSS MUTATED | 9 | 5 | 30 |
10P LOSS WILD-TYPE | 395 | 17 | 83 |
P value = 0.0651 (logrank test), Q value = 0.15
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
10Q LOSS MUTATED | 40 | 11 | 0.3 - 125.4 (26.6) |
10Q LOSS WILD-TYPE | 497 | 79 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
10Q LOSS MUTATED | 12 | 5 | 23 |
10Q LOSS WILD-TYPE | 392 | 17 | 90 |
P value = 1.48e-05 (logrank test), Q value = 9.2e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
11P LOSS MUTATED | 76 | 25 | 0.3 - 136.6 (25.5) |
11P LOSS WILD-TYPE | 461 | 65 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
11P LOSS MUTATED | 28 | 7 | 41 |
11P LOSS WILD-TYPE | 376 | 15 | 72 |
P value = 0.000163 (logrank test), Q value = 8e-04
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
11Q LOSS MUTATED | 73 | 22 | 0.3 - 136.6 (22.6) |
11Q LOSS WILD-TYPE | 464 | 68 | 0.1 - 225.5 (30.7) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
11Q LOSS MUTATED | 24 | 7 | 42 |
11Q LOSS WILD-TYPE | 380 | 15 | 71 |
P value = 0.000375 (logrank test), Q value = 0.0017
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
12P LOSS MUTATED | 45 | 16 | 8.2 - 118.2 (27.0) |
12P LOSS WILD-TYPE | 492 | 74 | 0.1 - 225.5 (30.3) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
12P LOSS MUTATED | 15 | 1 | 29 |
12P LOSS WILD-TYPE | 389 | 21 | 84 |
P value = 0.0526 (Fisher's exact test), Q value = 0.13
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
12P LOSS MUTATED | 28 | 3 | 4 | 5 |
12P LOSS WILD-TYPE | 343 | 19 | 12 | 35 |
P value = 0.000276 (logrank test), Q value = 0.0013
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
12Q LOSS MUTATED | 40 | 14 | 8.2 - 118.2 (26.0) |
12Q LOSS WILD-TYPE | 497 | 76 | 0.1 - 225.5 (30.4) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
12Q LOSS MUTATED | 10 | 2 | 28 |
12Q LOSS WILD-TYPE | 394 | 20 | 85 |
P value = 0.00068 (logrank test), Q value = 0.0029
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
13Q LOSS MUTATED | 92 | 25 | 0.3 - 149.6 (25.7) |
13Q LOSS WILD-TYPE | 445 | 65 | 0.1 - 225.5 (30.7) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
13Q LOSS MUTATED | 48 | 6 | 39 |
13Q LOSS WILD-TYPE | 356 | 16 | 74 |
P value = 0.00162 (logrank test), Q value = 0.0061
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
14Q LOSS MUTATED | 62 | 18 | 0.3 - 125.4 (27.6) |
14Q LOSS WILD-TYPE | 475 | 72 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
14Q LOSS MUTATED | 20 | 3 | 39 |
14Q LOSS WILD-TYPE | 384 | 19 | 74 |
P value = 0.00272 (logrank test), Q value = 0.0098
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
15Q LOSS MUTATED | 109 | 28 | 0.2 - 136.6 (24.1) |
15Q LOSS WILD-TYPE | 428 | 62 | 0.1 - 225.5 (31.9) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
15Q LOSS MUTATED | 37 | 9 | 63 |
15Q LOSS WILD-TYPE | 367 | 13 | 50 |
P value = 9.49e-06 (logrank test), Q value = 6.3e-05
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
16P LOSS MUTATED | 98 | 30 | 0.2 - 110.1 (27.6) |
16P LOSS WILD-TYPE | 439 | 60 | 0.1 - 225.5 (30.7) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
16P LOSS MUTATED | 35 | 6 | 58 |
16P LOSS WILD-TYPE | 369 | 16 | 55 |
P value = 0.0575 (Fisher's exact test), Q value = 0.14
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
16P LOSS MUTATED | 58 | 5 | 6 | 10 |
16P LOSS WILD-TYPE | 313 | 17 | 10 | 30 |
P value = 0.00374 (logrank test), Q value = 0.013
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
16Q LOSS MUTATED | 139 | 34 | 0.1 - 123.7 (28.6) |
16Q LOSS WILD-TYPE | 398 | 56 | 0.1 - 225.5 (30.6) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
16Q LOSS MUTATED | 57 | 7 | 76 |
16Q LOSS WILD-TYPE | 347 | 15 | 37 |
P value = 0.0599 (Fisher's exact test), Q value = 0.14
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
16Q LOSS MUTATED | 83 | 8 | 7 | 13 |
16Q LOSS WILD-TYPE | 288 | 14 | 9 | 27 |
P value = 4.07e-05 (logrank test), Q value = 0.00021
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
17P LOSS MUTATED | 128 | 37 | 0.2 - 136.6 (27.9) |
17P LOSS WILD-TYPE | 409 | 53 | 0.1 - 225.5 (30.1) |
P value = 0.0731 (Fisher's exact test), Q value = 0.17
nPatients | NO | YES |
---|---|---|
ALL | 290 | 224 |
17P LOSS MUTATED | 58 | 60 |
17P LOSS WILD-TYPE | 232 | 164 |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
17P LOSS MUTATED | 47 | 10 | 72 |
17P LOSS WILD-TYPE | 357 | 12 | 41 |
P value = 0.0847 (Fisher's exact test), Q value = 0.19
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
17P LOSS MUTATED | 80 | 8 | 6 | 13 |
17P LOSS WILD-TYPE | 291 | 14 | 10 | 27 |
P value = 0.0018 (logrank test), Q value = 0.0067
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
17Q LOSS MUTATED | 92 | 27 | 0.2 - 136.6 (29.2) |
17Q LOSS WILD-TYPE | 445 | 63 | 0.1 - 225.5 (30.0) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
17Q LOSS MUTATED | 39 | 8 | 46 |
17Q LOSS WILD-TYPE | 365 | 14 | 67 |
P value = 0.0679 (logrank test), Q value = 0.16
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
18P LOSS MUTATED | 50 | 12 | 0.1 - 136.6 (22.8) |
18P LOSS WILD-TYPE | 487 | 78 | 0.1 - 225.5 (30.4) |
P value = 0.00034 (Fisher's exact test), Q value = 0.0016
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
18P LOSS MUTATED | 26 | 5 | 20 |
18P LOSS WILD-TYPE | 378 | 17 | 93 |
P value = 0.0663 (Fisher's exact test), Q value = 0.15
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
18P LOSS MUTATED | 30 | 5 | 1 | 6 |
18P LOSS WILD-TYPE | 341 | 17 | 15 | 34 |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
18Q LOSS MUTATED | 29 | 6 | 28 |
18Q LOSS WILD-TYPE | 375 | 16 | 85 |
P value = 0.0723 (Fisher's exact test), Q value = 0.16
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
18Q LOSS MUTATED | 37 | 5 | 3 | 7 |
18Q LOSS WILD-TYPE | 334 | 17 | 13 | 33 |
P value = 0.00582 (logrank test), Q value = 0.02
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
19P LOSS MUTATED | 57 | 16 | 0.2 - 136.6 (25.5) |
19P LOSS WILD-TYPE | 480 | 74 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
19P LOSS MUTATED | 18 | 4 | 35 |
19P LOSS WILD-TYPE | 386 | 18 | 78 |
P value = 0.0873 (Fisher's exact test), Q value = 0.19
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
19P LOSS MUTATED | 33 | 4 | 4 | 4 |
19P LOSS WILD-TYPE | 338 | 18 | 12 | 36 |
P value = 0.0535 (logrank test), Q value = 0.13
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
19Q LOSS MUTATED | 54 | 14 | 0.2 - 136.6 (24.7) |
19Q LOSS WILD-TYPE | 483 | 76 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
19Q LOSS MUTATED | 18 | 4 | 32 |
19Q LOSS WILD-TYPE | 386 | 18 | 81 |
P value = 0.001 (Fisher's exact test), Q value = 0.004
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
20P LOSS MUTATED | 9 | 1 | 12 |
20P LOSS WILD-TYPE | 395 | 21 | 101 |
P value = 0.00135 (Fisher's exact test), Q value = 0.0052
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
20Q LOSS MUTATED | 3 | 2 | 6 |
20Q LOSS WILD-TYPE | 401 | 20 | 107 |
P value = 0.000828 (logrank test), Q value = 0.0034
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
21Q LOSS MUTATED | 54 | 17 | 0.3 - 125.4 (22.9) |
21Q LOSS WILD-TYPE | 483 | 73 | 0.1 - 225.5 (30.1) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
21Q LOSS MUTATED | 20 | 4 | 30 |
21Q LOSS WILD-TYPE | 384 | 18 | 83 |
P value = 0.000676 (logrank test), Q value = 0.0029
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
22Q LOSS MUTATED | 109 | 29 | 0.1 - 136.6 (27.1) |
22Q LOSS WILD-TYPE | 428 | 61 | 0.1 - 225.5 (30.3) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
22Q LOSS MUTATED | 47 | 10 | 53 |
22Q LOSS WILD-TYPE | 357 | 12 | 60 |
P value = 2.06e-05 (logrank test), Q value = 0.00011
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
XP LOSS MUTATED | 85 | 28 | 0.3 - 118.2 (27.3) |
XP LOSS WILD-TYPE | 452 | 62 | 0.1 - 225.5 (30.6) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
XP LOSS MUTATED | 34 | 5 | 47 |
XP LOSS WILD-TYPE | 370 | 17 | 66 |
P value = 0.0572 (Fisher's exact test), Q value = 0.14
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
XP LOSS MUTATED | 55 | 2 | 6 | 9 |
XP LOSS WILD-TYPE | 316 | 20 | 10 | 31 |
P value = 0.000752 (logrank test), Q value = 0.0031
nPatients | nDeath | Duration Range (Median), Month | |
---|---|---|---|
ALL | 537 | 90 | 0.1 - 225.5 (29.9) |
XQ LOSS MUTATED | 69 | 22 | 0.3 - 118.2 (28.9) |
XQ LOSS WILD-TYPE | 468 | 68 | 0.1 - 225.5 (30.0) |
P value = 1e-05 (Fisher's exact test), Q value = 6.3e-05
nPatients | ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA | MIXED SEROUS AND ENDOMETRIOID | SEROUS ENDOMETRIAL ADENOCARCINOMA |
---|---|---|---|
ALL | 404 | 22 | 113 |
XQ LOSS MUTATED | 31 | 4 | 35 |
XQ LOSS WILD-TYPE | 373 | 18 | 78 |
P value = 0.097 (Fisher's exact test), Q value = 0.21
nPatients | R0 | R1 | R2 | RX |
---|---|---|---|---|
ALL | 371 | 22 | 16 | 40 |
XQ LOSS MUTATED | 43 | 2 | 5 | 7 |
XQ LOSS WILD-TYPE | 328 | 20 | 11 | 33 |
-
Copy number data file = broad_values_by_arm.txt from GISTIC pipeline
-
Processed Copy number data file = /xchip/cga/gdac-prod/tcga-gdac/jobResults/GDAC_Correlate_Genomic_Events_Preprocess/UCEC-TP/22534123/transformed.cor.cli.txt
-
Clinical data file = /xchip/cga/gdac-prod/tcga-gdac/jobResults/Append_Data/UCEC-TP/22507145/UCEC-TP.merged_data.txt
-
Number of patients = 539
-
Number of significantly arm-level cnvs = 82
-
Number of selected clinical features = 4
-
Exclude regions that fewer than K tumors have mutations, K = 3
For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R
For binary or multi-class clinical features (nominal or ordinal), two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.